Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.

[1]  F. Pisano,et al.  Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder. , 2019, Actas urologicas espanolas.

[2]  M. Grimm,et al.  Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection , 2019, World Journal of Urology.

[3]  H. S. Kim,et al.  Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system , 2018, World Journal of Urology.

[4]  Y. Bao,et al.  The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette–Guérin therapy for bladder cancer , 2018, Medicine.

[5]  A. Briganti,et al.  Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. , 2018, Urologic oncology.

[6]  J. Witjes,et al.  Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. , 2018, European urology.

[7]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[8]  Alfred Rademaker,et al.  Genomic characterization of high-risk non-muscle invasive bladder cancer , 2016, Oncotarget.

[9]  M. L. Calle,et al.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.

[10]  G. Schäfer,et al.  Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer , 2016, Oncotarget.

[11]  Xifeng Wu,et al.  Novel fluorescence in situ hybridization‐based definition of bacille Calmette‐Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies , 2016, BJU international.

[12]  C. Dinney,et al.  Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. , 2016, European urology.

[13]  E. Kikuchi,et al.  Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin , 2016, BMC Urology.

[14]  J. Leow,et al.  Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients , 2014, British Journal of Cancer.

[15]  Y. Kohjimoto,et al.  External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin , 2014, International journal of urology : official journal of the Japanese Urological Association.

[16]  Jin Wook Kim,et al.  Predicting Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer in Korean Patients: A Comparison of the EORTC and CUETO Models , 2014, Korean journal of urology.

[17]  R. Medeiros,et al.  The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette‐Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population , 2014, BJU international.

[18]  Zhongqing Chen,et al.  Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer? , 2014, Cancer epidemiology.

[19]  Y. Lotan,et al.  Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder , 2013, British Journal of Cancer.

[20]  Tianyuan Xu,et al.  Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. , 2013, Urology.

[21]  Q. Trinh,et al.  Construction of predictive models for recurrence and progression in >1000 patients with non‐muscle‐invasive bladder cancer (NMIBC) from a single centre , 2013, BJU international.

[22]  F. Ajili,et al.  Prognostic Value of Tumor-associated Macrophages Count in Human Non-muscle-invasive Bladder Cancer Treated by BCG Immunotherapy , 2013, Ultrastructural pathology.

[23]  T. H. van der Kwast,et al.  Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer , 2012, BJU international.

[24]  V. Ficarra,et al.  Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio , 2012, Experimental and therapeutic medicine.

[25]  M. Nicolai,et al.  Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables , 2012, Urologia Internationalis.

[26]  Xifeng Wu,et al.  Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. , 2012, The Journal of urology.

[27]  T. Yoshino,et al.  Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette–Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder , 2011, Pathology international.

[28]  V. Hernández,et al.  External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer , 2011, World Journal of Urology.

[29]  F. Algaba,et al.  Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. , 2011, European urology.

[30]  S. Boorjian,et al.  The effect of gender on response to bacillus Calmette‐Guérin therapy for patients with non‐muscle‐invasive urothelial carcinoma of the bladder , 2010, BJU international.

[31]  Choal Hee Park,et al.  The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after Intravesical Bacillus Calmette-Guerin Instillation , 2010, Korean journal of urology.

[32]  F. Algaba,et al.  Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. , 2009, European urology.

[33]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[34]  H. Trindade,et al.  Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. , 2009, Urology.

[35]  L. Lacombe,et al.  Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. , 2009, European urology.

[36]  K. Aozasa,et al.  Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. , 2009, The Journal of urology.

[37]  D. Pode,et al.  The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. , 2007, The Journal of urology.

[38]  R. Tubbs,et al.  Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. , 2007, American journal of clinical pathology.

[39]  Brian J. Smith,et al.  The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. , 2006, The Journal of urology.

[40]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[41]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[42]  H. Woo,et al.  Management of stage T1 tumors of the bladder: International Consensus Panel. , 2005, Urology.

[43]  R. Millikan,et al.  Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Gu,et al.  Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer , 2005, Clinical Cancer Research.

[45]  Yi Luo,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2004, Cancer Research.

[46]  R. Sylvester,et al.  The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. , 2003, European urology.

[47]  S. Shariat,et al.  Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. , 2003, Urology.

[48]  C. Sternberg,et al.  Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. , 2002, Urology.

[49]  J. Patard,et al.  Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. , 2001, Urology.

[50]  K. Fan,et al.  Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. , 1997, Urology.

[51]  A. Jackson,et al.  Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. , 1994, Journal of clinical pathology.

[52]  Michael Cookson,et al.  Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. , 1992, The Journal of urology.

[53]  J. Smyth,et al.  Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. , 1992, The Journal of urology.

[54]  J. Gerdes,et al.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. , 1990, The Journal of urology.

[55]  T. Ratliff,et al.  Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. , 1987, Cancer research.

[56]  L. Collette,et al.  EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. , 2016, European urology.

[57]  A. Sahores,et al.  FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition. , 2016, The Journal of urology.

[58]  E. Castle,et al.  Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder. , 2014, Urologic oncology.

[59]  J. Gschwend,et al.  An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. , 2010, European urology.

[60]  J. Fitzpatrick,et al.  HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. , 2007, European urology.

[61]  K. Wakai,et al.  Evaluation of multiple recurrence events in superficial bladder cancer patients treated with intravesical bacillus Calmette-Guérin therapy using the Andersen-Gill's model , 2004, International Urology and Nephrology.